Share class: Ampliphi Biosciences Corp

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A136,183,06710,765,220 ( 29.75 %) 0 29.75 %

Major shareholders: Ampliphi Biosciences Corp

NameEquities%Valuation
Innoviva, Inc.
69.31 %
25,076,769 69.31 % 46 M $
Bank of America, NA (Charlotte, North Carolina)
1.752 %
634,047 1.752 % 1 M $
260,000 0.7186 % 481 000 $
Vanguard Global Advisers LLC
0.6226 %
225,287 0.6226 % 416 781 $
Geode Capital Management LLC
0.2959 %
107,066 0.2959 % 198 072 $
Edgewood Management LLC
0.2764 %
100,000 0.2764 % 185 000 $
Bridgeway Capital Management LLC
0.2083 %
75,382 0.2083 % 139 457 $
71,078 0.1964 % 131 494 $
Renaissance Technologies LLC
0.1285 %
46,496 0.1285 % 86 018 $
State Street Corp.
0.1114 %
40,300 0.1114 % 74 555 $
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Innoviva, Inc.69.31%
Other1.86%
Institutional1.85%
Individuals0.97%
State Street Corp.0.11%
Unknown25.9%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 73.13%
Individuals 0.97%

Based on 1000 largest holdings

Logo Ampliphi Biosciences Corp
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Employees
-
More about the company